May 29, 2025

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/ Madam,

Trading Symbol: ZOTA

Sub: Outcome of Board Meeting held on Thursday, May 29, 2025

Ref.: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject we, Zota Health Care Limited ("the Company") would like to inform you that the Board of Directors of the Company in its meeting held on Thursday, May 29, 2025 at 02:00 P.M., have *inter alia*, discussed and approved the following businesses:

1. Considered and approved standalone and consolidated audited financial results for the quarter and year ended on March 31, 2025 along with Audit Reports thereon. Financial Results and Audit Reports are enclosed herewith ***(Annexure - I).***

   We would like to inform you that M/s. Pradeep K. Singhi & Associates, Chartered Accountants, Statutory Auditors of the Company, have issued the Audit Reports with unmodified opinion. Further, standalone and consolidated audited financial results for the period as aforementioned shall be available on the website of the Stock Exchange where the shares of the Company are listed i.e. at www.nseindia.com and on Company's website at www.zotahealthcare.com

2. Recommended final dividend at the rate of 10% i.e. Re. 1/- per equity share of Rs. 10/- each for the financial year 2024-25, subject to the approval of shareholders at the ensuing Annual General meeting of the Company.

Registered Office:
Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat-395002 Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web: www.zotahealthcare.com

CIN: L24231GJ2000PLC038352

The Board meeting concluded at 08:05 P.M.

This is for your information and record.

Thanking You,

Yours Faithfully,

For **Zota Health Care Limited**

ASHVIN BHAGAVAN BHAI VARIYA

Digitally signed by ASHVIN BHAGAVANBHAI VARIYA
Date: 2025.05.29 20:44:47 +05'30'

Ashvin Variya
(Company Secretary & Compliance Officer)
Place: Surat

Encl: a/a

PRADEEP K SINGHI & ASSOCIATES
CHARTERED ACCOUNTANTS

Independent Auditor's Report on the Quarterly and Year to Date Audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of
ZOTA HEALTH CARE LIMITED

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying standalone quarterly and year to date financial results of **ZOTA HEALTH CARE LIMITED** (the "Company") for **the quarter and year ended March 31, 2025** ("Statement), attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us the Statement:

i. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India, of the net-profit and other comprehensive income and other financial information for the quarter and year ended March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the *"Auditor's Responsibilities for the Audit of the Standalone Financial Results"* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our

opinion.

Management's Responsibilities for the Standalone Financial Results

The Statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Ind AS, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence,

and where applicable, related safeguards.

Other Matters

The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2025 and the published figures of the year-to-date (nine months) ended December 31, 2024 , which were subjected to limited review, as required under the Listing Regulations.

For Pradeep K. Singhi & Associates
Chartered Accountants
FRN : 0126027W

PRADEEP KUMAR SINGHI
Digitally signed by PRADEEP KUMAR SINGHI
Date: 2025.05.29 20:05:39 +05'30'

Pradeep Kumar Singhi
(Partner)
UDIN: 25024612BMONJH5137

Date: 29-05-2025
Place: Surat

zota® healthcare ltd.

ZOTA HEALTH CARE LIMITED

Audited Standalone Financial Results for the Quarter and Year ended 31st March, 2025

(Amt. ₹ in lakhs, except per share data)

	Particulars	Quarter Ended			Year Ended	
		31-03-2025 (Audited)	31-12-2024 (Unaudited)	31-03-2024 (Audited)	31-03-2025 (Audited)	31-03-2024 (Audited)
I.	Revenue from Operations	7793.25	6813.08	4734.96	25727.61	16658.50
II.	Other Income	149.53	168.91	69.38	462.34	205.19
III.	**Total Income**	**7942.78**	**6981.99**	**4804.33**	**26189.94**	**16863.69**
IV.	**Expenses:**					
	Cost of Materials Consumed	609.03	303.90	293.75	1622.76	1277.46
	Purchases of Stock-in-Trade	5577.95	4699.98	3565.39	15530.50	9520.35
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	0.00 (1445.69)	(943.99)	(1054.65)	(1614.25)	(352.67)
	Employee Benefit Expenses	886.75	854.97	613.12	3114.97	1997.36
	Finance Costs	7.93	3.83	6.42	105.59	36.47
	Depreciation / Amortisation and Depletion Expense	94.37	81.75	85.86	317.11	300.73
	Other Expenses	1770.49	1767.41	1278.83	5928.92	3593.37
	Total Expenses	**7500.83**	**6767.84**	**4788.71**	**25005.61**	**16373.07**
V.	Profit before Exceptional items and tax from continuing operations (III-IV)	441.95	214.15	15.62	1184.33	490.61
VI.	Exceptional Items		-	-		-
VII.	Profit/(loss) before tax	441.95	214.15	15.62	1184.33	490.61
VIII.	Tax Expense:					
	(1) Current tax	203.91	(15.23)	14.04	338.13	153.08
	(1.1) I.T. & DD Tax Provision Created Short/ excess	(0.00)	(2.49)	-	(2.49)	(6.28)
	(2) Deferred Tax	22.29	(24.10)	20.74	13.03	(5.82)
IX.	Profit/ (Loss) for the period from Continuing Operations (VII-VIII)	260.33	207.77	22.33	861.72	337.99
X.	Profit/(loss) before tax from discontinued operations	-	-	-		-
XI.	Tax Expense of discontinued Operations		-	-		-
XII.	Profit/ (Loss) from Discontinued Operations (after Tax) (X- XI)		-	-		-
XIII.	**Profit/ (Loss) for the period**	**260.33**	**207.77**	**22.33**	**861.72**	**337.99**
XIV.	**Other Comprehensive Income**					
	A (i) Items that will not be reclassified to Statement of profit and loss	6.13	22.94	3.88	19.11	19.82
	(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	(1.54)	(5.77)	(0.98)	(4.81)	(4.99)
	B (i) Items that will be reclassified to Statement of profit and loss	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to profit and loss	-	-	-	-	-
	Other comprehensive income for the period, net of tax	4.58	17.17	2.90	14.30	14.83
	Total comprehensive income for the period (XIII + XIV)	**264.91**	**224.94**	**25.23**	**876.01**	**352.82**
	Paid-up Equity Share Capital	2863.50	2757.10	2584.73		2584.73
	Other Equity					9592.80
	Earnings per equity share of face value of ` 10 each					
	(1) Basic (in ₹)	0.92	0.76	0.09	3.16	1.32
	(2) Diluted (in ₹)	0.86	0.70	0.08	2.91	1.29

* denotes figures less than a lakh

For and on behalf of the Board

(Whole Time Director)	(Managing Director)	
Himanshu M. Zota	Moxesh K. Zota	
(Din : 01097722)	(Din : 07625219)	
Company Secretary	Chief Financial Officer	Group CEO
Ashvin Variya	Viral Mandviwala	Sujit Paul

Date: 29-05-2025
Place : Surat

ZOTA HEALTHCARE LTD.

For Pradeep K. Singhi & Associates
Chartered Accountants
Firm No. 0126027W

PRADEEP KUMAR SINGHI
Digitally signed by PRADEEP KUMAR SINGHI
Date: 2025.05.29 20:06:17 +05'30'

Pradeep Kumar Singhi
(Partner)
M. No. 200/024612

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

CIN : L24231GJ2000PLC038352

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj) India
Ph: +91 261 2397122

ZOTA HEALTH CARE LIMITED

zota® healthcare ltd.

Standalone Cash Flow Statement for the Year ended 31st March, 2025

(Amt. ₹ in Lakhs)

	PARTICULARS	For the Year Ended on 31st March, 2025	For the Year Ended on 31st March, 2024
A	**CASH FLOW FROM OPERATING ACTIVITIES**		
	Net Profit Before Tax as per Statement of Profit and Loss	1184.33	490.61
	Adjusted for:		
	Exceptional items	-	-
	Depreciation / Amortisation and Depletion Expense	317.11	300.73
	Employee stock option expense	59.47	34.87
	Finance Costs	49.76	3.44
	Interest Income	(435.06)	(184.66)
	Operating Profit before Working Capital Changes and other adjustments:	**1175.62**	**645.00**
	Adjusted for:		
	Inventories	(1949.39)	(422.68)
	Trade Receivables	(2932.66)	(3014.76)
	Trade Payables	1538.51	601.83
	Other Current Liabilities and Provisions	951.02	59.60
	Provisions - Non-Current	61.56	23.95
	Current Financial Assets	(523.16)	(717.71)
	Other Current Assets	(202.50)	(37.89)
	Changes in Working Capital	**(3056.61)**	**(3507.66)**
	Cash Generated from Operations	**(1880.99)**	**(2862.66)**
	Direct Taxes Paid	(340.45)	(151.79)
	Net Cash Flow from/(used in) Operating Activities	**(2221.44)**	**(3014.46)**
B	**CASH FLOW FROM INVESTING ACTIVITIES**		
	Acquisition of property, plant and equipment, capital work-in-progress and intangible assets	**(425.94)**	(530.62)
	Proceeds from disposal of Intangible Assets	-	10.19
	Decrease in Long Term Loans & Advances	(3846.89)	(807.76)
	Interest Received	435.06	184.66
	Non-current Investments	(10946.95)	276.87
	Net Cash Flow from/(used in) Investing Activities	**(14784.73)**	**(866.66)**
C	**CASH FLOW FROM FINANCING ACTIVITIES**		
	Proceeds from Issue of Equity Share Capital	278.77	68.70
	Increase in Securities Premium Reserve	14835.71	2012.91
	Money received against Share warrants	3783.45	520.40
	Increase in short-term Borrowings	(1447.21)	1467.67
	Finance Costs paid	(49.76)	(3.44)
	Dividend Paid	(274.08)	(258.47)
	Net Cash Flow from / (used in) Financing Activities	**17126.88**	**3807.77**
	Net Increase/(Decrease) in Cash & Cash Equivalents	120.71	(73.35)
	Opening Balance of Cash and Cash Equivalents	14.28	87.63
	Closing Balance of Cash and Cash Equivalents	**134.99**	**14.28**

For and on behalf of the Board

ZOTA HEALTHCARE LTD.

(Whole Time Director)	(Managing Director)
Himanshu M. Zota	Moxesh K. Zota
(Din : 01097722)	(Din : 07625219)
34,Ichhanath Umra, Surat.	8D,Lal Bunglow, Surat.

Company Secretary	Chief Financial Officer	Group CEO
Ashvin Variya	Viral Mandviwala	Sujit Paul

Date: 29-05-2024
Place: Surat

For Pradeep K. Singhi & Associates
Chartered Accountants
Firm No. 0126027W

PRADEEP KUMAR SINGHI

Digitally signed by PRADEEP KUMAR SINGHI
Date: 2025.05.29 20:06:36 +05'30'

Pradeep Kumar Singhi
(Partner)
M. No. 200/024612

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

CIN : L24231GJ2000PLC038352

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

Independent Auditor's Report on the Quarterly and Year to Date Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of
ZOTA HEALTH CARE LIMITED

Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying Statement of Consolidated Financial Results of **ZOTA HEALTH CARE LIMITED** ("Holding company") and its subsidiaries (holding company and its subsidiaries together referred to as "the Group"), for **the quarter and year ended March 31, 2025** ("the Statement"), attached herewith, being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements of subsidiaries, the Statement:

a. includes the results of the following entities:
    - Zota Health Care Limited (Parent)
    - Zota Healthcare Lanka (Pvt) Ltd (Wholly Owned Subsidiary)
    - Davaindia Health Mart Limited (Wholly Owned Subsidiary)
    - Zota Nex Tech Limited (Wholly Owned Subsidiary)
    - Everyday Herbal Beauty Care Private Limited (Subsidiary)
    - Everyday Herbal Beauty And Wellness Care Private Limited (Subsidiary)

b. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations, as amended; and
c. gives a true and fair view, in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of consolidated total comprehensive income (comprising of net-profit/(loss) and other comprehensive income) and other financial information of the Group for the quarter and year ended March 31, 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the *"Auditor's Responsibilities for the Audit of the Consolidated Financial Results"* section of our report. We are independent of the Group in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in

accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Consolidated Financial Results

The Statement has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of the Statement that give a true and fair view of the net-profit and other comprehensive income and other financial information of the Group in accordance with the applicable accounting standards prescribed under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the

economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its associates and jointly controlled entities to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial information of the entities within the Group to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters

The Statement includes the audited Financial Statements of 5 subsidiaries, whose financial statements reflect total assets of Rs. 25467.29 Lakhs as at March 31, 2025 and total revenues of Rs. 12146.72 Lakhs, total net loss of Rs. 6184.14 lakhs and total comprehensive loss of Rs. 6168.30 lakhs and cash inflows (net) Rs. 140.63 lakhs for the year ended March 31 2025, as considered in the consolidated financial results, which have been audited by their respective independent auditors.

The independent auditors' reports on the financial statements of these entities have been furnished to us by the Management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.

Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the Financial Results certified by the Board of Directors.

Further, in addendum to paragraph 1 of this report, we report that the figures for the quarter ended March 31, 2025 represents the derived figures between the audited figures of the financial year ended March 31, 2025 and the published figures of the year-to-date (nine months) ended December 31, 2024 , which were subjected to limited review.

For Pradeep K. Singhi & Associates
Chartered Accountants
FRN : 0126027W

PRADEEP KUMAR SINGHI

Digitally signed by PRADEEP KUMAR SINGHI
Date: 2025.05.29 20:06:56 +05'30'

Pradeep Kumar Singhi
(Partner)
UDIN: 25024612BMONJI3113

Date: 29-05-2025
Place: Surat

zota®
healthcare ltd.

ZOTA HEALTH CARE LIMITED

Audited Consolidated Financial Results for the Quarter and Year ended 31st March, 2025

(Amt. ₹ in lakhs, except per share data)

	Particulars	Quarter Ended			Year Ended	
		31-03-2025 (Audited)	31-12-2024 (Unaudited)	31-03-2024 (Audited)	31-03-2025 (Audited)	31-03-2024 (Audited)
I.	Revenue from Operations	9727.46	7212.38	4963.56	29297.48	18048.85
II.	Other Income	100.15	50.59	45.68	206.80	115.61
III.	**Total Income**	**9827.61**	**7262.97**	**5009.25**	**29504.28**	**18164.46**
IV.	**Expenses:**					
	Cost of Materials Consumed	609.03	303.90	293.75	1622.76	1277.46
	Purchases of Stock-in-Trade	6221.19	4808.81	3565.39	16257.53	9520.35
	Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in Trade	(2042.73)	(1929.48)	(1580.06)	(4149.96)	(1127.79)
	Employee Benefit Expenses	2593.62	2381.99	1211.38	8606.62	3045.05
	Finance Costs	345.80	157.40	168.09	1078.34	478.82
	Depreciation / Amortisation and Depletion Expense	1431.50	1134.53	679.87	4319.61	2008.51
	Other Expenses	2099.69	2254.22	1621.61	7533.82	4578.35
	Total Expenses	**11258.09**	**9111.37**	**5960.05**	**35268.71**	**19780.75**
V.	Profit before Exceptional Items and tax from continuing operations (III-IV)	(1430.49)	(1848.40)	(950.81)	(5764.43)	(1616.29)
VI	Exceptional Items	-	-	-	-	-
VII.	Profit/(loss) before tax	(1430.49)	(1848.40)	(950.81)	(5764.43)	(1616.29)
VIII.	Tax Expense:					
	(1) Current tax	203.91	(15.23)	14.04	338.13	153.08
	(1.1) I.T. & DD Tax Provision Created Short/ excess	(0.00)	(2.49)	-	(2.49)	(6.28)
	(2) Deferred Tax	345.54	(63.86)	273.08	426.19	328.31
IX.	Profit/ (Loss) for the period from Continuing Operations (VII-VIII)	(1288.86)	(1894.54)	(691.77)	(5673.89)	(1434.79)
X.	Profit/(loss) before tax from discontinued operations	-	-	-		-
XI.	Tax Expense of discontinued Operations	-	-	-		-
XII.	Profit/ (Loss) from Discontinued Operations (after Tax) (X-XI)	-	-	-		-
XIII.	**Profit/ (Loss) for the period**	**(1288.86)**	**(1894.54)**	**(691.77)**	**(5673.89)**	**(1434.79)**
XIV.	**Other Comprehensive Income**					
	A (i) Items that will not be reclassified to Statement of profit and loss	15.89	34.81	8.08	40.31	24.59
	(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	(3.98)	(8.74)	(2.03)	(10.11)	(6.18)
	B (i) Items that will be reclassified to Statement of profit and loss	(0.01)	0.03	(0.04)	(0.05)	(0.07)
	(ii) Income Tax relating to items that will be reclassified to profit and loss	*	*	0.01	0.01	0.02
	Other comprehensive income for the period, net of tax	11.90	26.09	6.03	**30.16**	**18.36**
	Total comprehensive income for the period (XIII + XIV)	**(1276.96)**	**(1868.45)**	**(685.74)**	**(5643.73)**	**(1416.42)**
	Profit attributable to:					
	Owners of the parent	(1289.04)	(1868.17)	(691.77)	(5639.84)	(1434.79)
	Non-controlling interest	0.18	(26.37)		(34.05)	-
	Other comprehensive income attributable to:					
	Owners of the parent	11.90	26.09	6.03	30.16	18.36
	Non-controlling interest	-	-			-
	Total Comprehensive Income attributable to:					
	Owners of the parent	(1277.14)	(1842.08)	(685.74)	(5609.68)	(1416.42)
	Non-controlling interest	0.18	(26.37)	-	(34.05)	-
	Paid-up Equity Share Capital	2863.50	2757.10	2584.73	2863.50	2584.73
	Other Equity				19504.98	6412.92
	Earnings per equity share of face value of ` 10 each					
	(1) Basic (in `)	(4.57)	(6.80)	(2.68)	(20.68)	(5.59)
	(2) Diluted (in `)	(4.28)	(6.31)	(2.62)	(19.06)	(5.47)

* denotes figures less than a lakh

For and on behalf of the Board

(Whole Time Director)
Himanshu M. Zota
(Din : 01097722)

(Managing Director)
Moxesh K. Zota
(Din : 07625219)

ZOTA HEALTHCARE LTD.

Company Secretary
Ashwin Variya

Chief Financial Officer
Viral Mandviwala

Group CEO
Sujit Paul

Date: 29-05-2025
Place : Surat

For Pradeep K. Singhi & Associates
Chartered Accountants
Firm No. 0126027W

PRADEEP KUMAR SINGHI
Digitally signed by PRADEEP KUMAR SINGHI
Date: 2025.05.29 20:07:15 +05'30'

Pradeep Kumar Singhi
(Partner)
M. No. 200/024612

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

CIN : L24231GJ2000PLC038352

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

zota® healthcare ltd.

ZOTA HEALTH CARE LIMITED

Consolidated Cash Flow Statement For the Year Ended 31st March, 2025

(Amt. ₹ in Lakhs)

	PARTICULARS		For the Year Ended on 31st March, 2025	For the Year Ended on 31st March, 2024
A	**CASH FLOW FROM OPERATING ACTIVITIES**			
	Net Profit Before Tax as per Statement of Profit and Loss		(5764.43)	(1616.29)
	Adjusted for:			
	Exceptional items		-	-
	Depreciation / Amortisation and Depletion Expense		4319.61	2008.51
	Employee stock option expense		59.47	34.87
	Loss on sale of Property Plant & Equipment		0.81	0.00
	Finance Costs		1078.34	419.21
	Interest Income		(343.44)	(93.69)
	Operating Profit before Working Capital Changes		**(649.65)**	**752.61**
	Adjusted for:			
	Inventories		(5191.77)	(1197.80)
	Trade Receivables		(1325.76)	(3026.23)
	Trade Payables		879.50	3799.31
	Other Current Liabilities and Provisions		1860.37	607.12
	Provisions - Non-Current		231.89	23.95
	Current Financial Assets		(39.02)	(717.71)
	Other Current Assets		(413.75)	(686.68)
	Changes in Working Capital		**(3998.54)**	**(1198.04)**
	Cash Generated from Operations		**(4648.19)**	**(445.43)**
	Taxes Paid		**(348.24)**	(152.99)
	Net Cash Flow from/(Used in) Operating Activities	**(A)**	**(4996.43)**	**(598.42)**
B	**CASH FLOW FROM INVESTING ACTIVITIES**			
	Acquisition of property, plant and equipment, capital work-in-progress and intangible assets		(4597.78)	(1671.02)
	Proceeds from disposal of Intangible Assets		-	10.19
	Proceeds from disposal of Property, Plant and Equipment		1.10	-
	Interest Received		343.44	93.69
	Non-current Investments		(4965.35)	276.87
	Net Cash Flow (Used in) Investing Activities	**(B)**	**(9218.59)**	**(1290.28)**
C	**CASH FLOW FROM FINANCING ACTIVITIES**			
	Proceeds from Issue of Equity Share Capital		278.77	75.20
	Increase in Securities Premium Reserve		14835.71	2012.91
	Money received against Share warrants		3783.45	520.40
	Increase in short-term Borrowings		(1406.72)	1467.67
	Principal payment of lease liability		(2172.02)	(1030.87)
	Interest payment of lease liability		(826.51)	(415.77)
	Finance Costs		(241.73)	(3.44)
	Loans		499.48	(490.00)
	Dividend Paid		(274.08)	(258.47)
	Net Cash Flow from / (Used in) Financing Activities	**(C)**	**14476.35**	**1877.63**
	Net Increase/(Decrease) in Cash & Cash Equivalents	**(A+B+C)**	261.34	(11.06)
	Effect of Exchange differences on cash and cash equivalents held in foreign currency		0.10	0.04
	Opening Balance of Cash and Cash Equivalents		100.47	111.50
	Closing Balance of Cash and Cash Equivalents		**361.91**	**100.47**

As per our report of even date
For and on behalf of the Board

(Whole Time Director)
Himanshu M. Zota
(Din : 01097722)
34,Ichhanath Umra, Surat.,

(Managing Director)
Moxesh K. Zota
(Din : 07625219)
8D,Lal Bunglow, Surat.,

ZOTA HEALTHCARE LTD.

Company Secretary
Ashvin Variya

Chief Financial Officer
Viral Mandviwala

Group CEO
Sujit Paul

Date: 29-05-2024
Place: Surat

For Pradeep K. Singhi & Associates
Chartered Accountants
Firm No. 0126027W

PRADEEP KUMAR SINGHI
Digitally signed by PRADEEP KUMAR SINGHI
Date: 2025.05.29 20:07:32 +05'30'

Pradeep Kumar Singhi
(Partner)
M. No. 200/024612

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

CIN : L24231GJ2000PLC038352

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

zota®
healthcare ltd.

Notes:

1. The above financial results for the quarter and year ended March 31, 2025 have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on May 29, 2025.

2. The financial results have been prepared in accordance with the Indian Accounting Standards ("Ind As") as prescribed under section 133 of the Companies Act, 2013 read with (Indian Accounting Standards) rules, 2015, as amended.

3. The figures for quarter ended March 31, 2025 are balancing figures between the audited figures of the financial year ended March 31, 2025 and the published figures of the year-to-date (nine months) ended December 31, 2024, which were subjected to limited review report.

4. The Statutory Auditors have provided Standalone and Consolidated Audit Reports for the quarter and year ended March 31, 2025 with unmodified option.

5. The Board of Directors has recommended dividend at the rate of 10% i.e. Re. 1/- per equity share of Rs. 10/- each for the financial year 2024-25, which is subject to approval of the members in ensuing Annual General Meeting.

6. The company has evaluated its Operating segment in accordance with Ind As 108 and has concluded that it is engaged in a single operating segment.

7. The consolidated results include the result of following companies:
   A) Wholly owned subsidiaries:
      i) Zota Healthcare Lanka (Pvt) Ltd
      ii) Davaindia Health Mart Limited
      iii) Zota Nex Tech Limited
   B) Subsidiaries:
      i) Everyday Herbal Beauty Care Private Limited
      ii) Everyday Herbal Beauty and Wellness Care Private Limited

8. In the consolidated financial results, the Company has adopted Ind As 116 'Leases' and applied the Standard to its leases. This has resulted in recognizing a Right-of-Use Asset of Rs. 12538.11 lakhs and a corresponding Lease Liability of Rs. 13399.94 lakhs as at March 31, 2025. The impact of this on the consolidated profit for the quarter and year ended March 31, 2025 is Rs. 49.58 lakhs and Rs. 534.88 lakhs respectively.

9. During the quarter; upon receipt of balance 75% amount i.e. Rs. 381.75/- per warrant of the warrants issue price, the Board of Directors of the Company has on January 13, 2025 and February 13, 2025 allotted 2,23,080 and 88,407 equity shares upon conversion of warrants to 8 and 2 Warrant Holders respectively.

10. During the quarter, the Company has issued and allotted 7,52,500 equity shares of Rs. 10/- each on a preferential basis at Rs. 820/- per equity share on February 20, 2025.

Registered Office :
Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

CIN : L24231GJ2000PLC038352

Plant :
Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

ZOTA HEALTHCARE LTD.

zota®
healthcare ltd.

11. The Company has during the quarter issued and allotted 7,52,500 Fully convertible warrants each convertible into equivalent number of fully paid up equity share of the Company of face value of Rs.10/- each on a preferential basis at Rs. 820/- per warrant on February 20, 2025 upon receipt of the upfront money Rs. 1542.63 lakhs being 25% of warrant issue price (i.e. Rs. 205/-) per warrant. Balance 75% of warrant issue price (i.e. Rs. 615/-) per warrant shall be payable within 18 months from the date of allotment on exercise of rights attached to the warrants.

12. For the financial year ended March 31, 2025; the total outstanding warrants to be converted into equity shares were 21,69,924 which were allotted on August 14, 2024 upon receipt of upfront amount of 25% of the warrant issue price i.e. Rs. 127.25/- per warrant.

13. During the year, the company has granted 30,430 stock options under Zota Health Care - Employee Stock Option Plan 2022' ("ZHL ESOP 2022"). As on March 31, 2025, the Company has on cumulative basis granted 43,230 stock options under Zota Health Care - Employee Stock Option Plan 2022. Further, the options granted are yet to be exercised.

14. During the quarter, Company has made an investment of Rs. 5539.94 lakhs by subscribing 1,33,332 equity shares of M/s Davaindia Health Mart Limited at the price of Rs. 4155 (including premium of Rs. 4145) per shares.

15. Figures pertaining to the previous period have been regrouped/rearranged, reclassified and restated wherever considered necessary, to make them comparable with those of current period.

ZOTA HEALTHCARE LTD.

Registered Office :
Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

CIN : L24231GJ2000PLC038352

Plant :
Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

zota® healthcare ltd.

ZOTA HEALTH CARE LIMITED

Standalone and Consolidated Audited Statement of Assets and Liabilities

(Amt. ₹ in lakhs)

	Particulars	Standalone		Consolidated	
		As at 31st March, 2025 Audited	As at 31st March, 2024 Audited	As at 31st March, 2025 Audited	As at 31st March, 2024 Audited
	ASSETS				
(1)	**Non-Current Assets**				
	Property, plant and equipment	845.61	787.65	5598.94	2356.63
	Right-of-use assets	-	-	12538.11	7506.83
	Intangible Assets	379.62	406.57	401.37	406.57
	Capital work-in-progress	557.58	479.77	557.58	479.77
	Intangible assets under development	-	-	90.25	-
	Financial Assets				
	(i) Investments	11623.96	677.00	5435.30	469.95
	(iii) Loans	5921.96	2075.06	11.02	11.02
	Deferred tax assets (Net)	15.66	2.63	865.22	440.29
	Other Non-current assets	-	-	-	-
	Total Non-Current assets	**19344.38**	**4428.68**	**25497.79**	**11671.05**
(2)	**Current Assets**				
	Inventories	5955.53	4006.14	10568.38	5376.61
	Financial Assets				
	(i) Trade Receivables	10303.88	7371.22	4050.15	2724.39
	(ii) Cash and Cash Equivalents	0.52	0.56	213.21	67.67
	(iii) Bank balance other than cash and cash equivalents	134.46	13.72	148.70	32.80
	(iv) Loans	1793.78	1270.62	1699.06	1660.03
	Other Current Assets	439.73	237.22	1736.76	1300.28
	Total Current assets	18627.91	12899.49	18416.26	11161.80
	Total Assets	**37972.29**	**17328.17**	**43914.05**	**22832.85**
	EQUITY AND LIABILITIES				
(1)	**Equity**				
	(i) Equity Share capital	2863.50	2584.73	2863.50	2584.73
	(ii) Other Equity	28873.37	9592.80	19504.98	6412.92
	Non-controlling interest	-	-	347.00	-
	Total Equity (Refer Note 1)	**31736.87**	**12177.54**	**22715.48**	**8997.66**
(2)	**Liabilities**				
	Non-Current Liabilities				
	Financial Liabilities				
	(i) Borrowings	-	-	499.48	-
	(ii) Lease liabilities	-	-	10255.49	6316.42
	Provisions	179.34	117.78	382.21	150.32
	Total non-current liabilities	**179.34**	**117.78**	**11137.19**	**6466.74**
	Current liabilities				
	Financial Liabilities				
	(i) Borrowings	20.46	1467.67	60.95	1467.67
	(ii) Lease liabilities	-	-	3144.45	1744.37
	(ii) Trade payables	-	-	-	-
	- Total oustanding dues of micro enterprises and small enterprises	1248.17	742.21	1248.17	742.21
	- Total Oustanding dues of Creditors other than micro enterprises and small enterprises	3374.44	2341.88	2991.91	2618.36
	Other Current liabilities	759.56	131.09	1008.34	161.74
	Provisions	653.45	350.01	1607.55	634.10
	Total current liabilities	6056.08	5032.86	10061.38	7368.45
	Total Liabilities	6235.41	5150.64	21198.57	13835.19
	Total Equity and Liabilities	**37972.29**	**17328.17**	**43914.05**	**22832.85**

For and on behalf of the Board

(Whole Time Director)	(Managing Director)		
Himanshu M. Zota	Moxesh K. Zota		
(Din : 01097722)	(Din : 07625219)		
Company Secretary	Chief Financial Officer	Group CEO	
Ashvin Variya	Viral Mandviwala	Sujit Paul	

Date: 29-05-2025
Place : Surat

For Pradeep K. Singhi & Associates
Chartered Accountants
Firm No. 0126027W

PRADEEP KUMAR SINGHI Digitally signed by PRADEEP KUMAR SINGHI Date: 2025.05.29 20:07:55 +05'30'

Pradeep Kumar Singhi
(Partner)
M. No. 200/024612

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

CIN : L24231GJ2000PLC038352

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

zota®
healthcare ltd.

May 29, 2025

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400051

Dear Sir/ Madam,

Sub: Declaration pursuant to regulation 33(3)(d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 in respect of Audit Reports with unmodified opinion

I, Himanshu Zota, Whole-time Director of Zota Health Care Limited, hereby declare that M/s Pradeep K. Singhi & Associates, Chartered Accountants (Firm Reg. No. 0126027W), Statutory Auditors of the Company have issued Audit Reports with unmodified opinion on Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2025.

This declaration is being given in accordance with Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as amended, and SEBI Circular No.: CIR/CFD /CMD/56/2016 dated May 27, 2016.

Kindly take this on your record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

ZOTA HEALTHCARE LTD.

Himanshu Muktilal Zota
(Whole-time Director)
DIN: 01097722

Place: Surat

Registered Office :
Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

CIN : L24231GJ2000PLC038352

Plant :
Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122